Related Experiment Video

Updated: Dec 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Tivozanib in renal cell carcinoma: a new approach to previously treated disease

Nicholas J Salgia1, Zeynep B Zengin1, Sumanta K Pal2

  • 1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Therapeutic Advances in Medical Oncology
|June 18, 2020
PubMed

Insights

Tivozanib, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF-TKI), is a key targeted therapy for renal cell carcinoma (RCC). This review analyzes its efficacy in phase III trials and potential in combination therapies for RCC management.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted therapies, particularly vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-TKIs), have been central to renal cell carcinoma (RCC) treatment for 20 years.
  • Tivozanib is a highly selective VEGF-TKI with extensive preclinical and clinical data supporting its investigation.

Purpose of the Study:

  • To review tivozanib's role in renal cell carcinoma (RCC) treatment.
  • To analyze preclinical, early clinical, and phase III trial data (TIVO-1, TIVO-3) for tivozanib in RCC.
  • To explore ongoing trials, combination therapies, and tivozanib's clinical utility in managing RCC.

Main Methods:

  • Review of preclinical studies and clinical trials, including phase III trials TIVO-1 and TIVO-3.
  • Analysis of data from prospective, multi-institutional trials.
  • Exploration of ongoing and planned investigations of tivozanib.

Main Results:

  • Tivozanib demonstrates significant investigation within the RCC treatment landscape.
  • Phase III trials TIVO-1 and TIVO-3 provide robust data on its efficacy.
  • Further trials are evaluating tivozanib in combination therapies and varied disease settings.

Conclusions:

  • Tivozanib is a well-characterized VEGF-TKI with a significant role in renal cell carcinoma (RCC) management.
  • Its selective inhibition of VEGF receptors supports its utility as a clinical tool.
  • Ongoing research continues to define the expanding role of tivozanib in RCC therapy.
Keywords:
TIVO-1TIVO-3renal cell carcinomativozanibvascular endothelial growth factor receptor tyrosine kinase

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

959

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
337
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
347
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
366
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
582